(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…
Search results for: cardiovascular risk
Plasma Complement Activation in Rheumatic Diseases May Accelerate Coronary Artery Disease
A recent study examined the relationship between complement activation and coronary artery disease in patients with rheumatic disease. Researchers found these patients had higher plasma terminal complement complexes and more complement activation in the vascular adventitia, which may accelerate cardiovascular disease and act as a target for new therapies…
Insufficient Evidence Regarding Osteoporosis Medications in Kidney Patients
NEW YORK (Reuters Health)—There are insufficient data to make evidence-based decisions regarding the benefits and harms of osteoporosis medications in patients with chronic kidney disease (CKD), according to a systematic review and meta-analysis. “We found low to moderate evidence for the effects of some but not all of the medications, and the evidence was limited…
How to Leverage Physical Therapy & Technology to Help Patients Stay Fit & Decrease Pain
For patients living with rheumatic diseases, the benefits of physical therapy and exercise cannot be overstated. “Working with a physical therapist provides a chance for careful evaluation of how the patient is moving and experiencing pain,” says Maura Iversen, BSc, PT, DPT, SD, MPH…
Anti-Interleukin-6 Therapy for Erdheim-Chester Disease Warrants Study
Erdheim-Chester disease (ECD) is a rare, non-Langerhan’s cell histiocytosis characterized by tissue infiltration of CD68-positive and CD1a-negative foamy histiocytes.1 ECD was discovered as a lipid granulomatosis in 1930 by Jakob Erdheim and his pupil, William Chester, and approximately 500 cases have been described to date.1 ECD has a heterogeneous course and prognosis ranging from an…
Rheumatology Research Clears Paths to Improved Arthritis Patient Care, Long-Term Health
WASHINGTON, D.C.—Rheumatology researchers look for next-generation treatments, healthy interventions, and genetic and microbial clues to disease pathogenesis and therapy response, according to new studies presented at a Nov. 15, 2016, press conference at the 2016 ACR/ARHP Annual Meeting. OA & Physical Function How do you know when a patient with knee osteoarthritis (OA) has the…
Medical Paradoxes in Clinic, Lab Should Encourage Physicians to Reappraise Ideas about Health and Disease
Wash your hands. This most basic tenet of proper hygiene has been drummed into our heads for years. It’s an obvious infection prevention activity, yet for years, compliance among physicians and other caregivers has been lackluster. To rectify this matter, regulatory agencies began auditing hospital staff adherence to this axiom of infection prevention. Not only…
Gout Treatments Effective If Patients Maintain Lifelong Adherence to Therapies
Although gout is one of the most effectively treated of all rheumatic diseases, it is among the worst-managed diseases long term, as shown by many studies. “Treatments are excellent, yet are dramatically under-utilized,” says Theodore Fields, MD, FACP, rheumatologist, Hospital for Special Surgery (HSS), New York. “This is because some gout patients feel better between…
Clinicians May Have Inaccurate Views of Benefits, Harms of Treatments & Tests
NEW YORK (Reuters Health)—Clinicians’ expectations of the benefits and harms of a wide range of treatments and tests are rarely accurate, according to a new study. “There was variation—with benefits and harms sometimes being overestimated and sometimes being underestimated; but there was a tendency for clinicians to more often underestimate (rather than overestimate) harms and…
Statin Use Tied to Attenuation of Tocilizumab-Mediated Lipid Increases
NEW YORK (Reuters Health)—Statin treatment is associated with an attenuation of the increases in serum lipids experienced by rheumatoid arthritis patients on tocilizumab, according to a post-hoc analysis of clinical trials. Treatment with the interleukin-6 receptor-alpha inhibitor tocilizumab is known to raise total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride levels. To explore the possible effect of…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 54
- Next Page »